Madrigal pharmaceuticals provides corporate updates and reports 2022 fourth quarter and full year financial results

Conshohocken, pa., feb. 23, 2023 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today provides a summary of corporate updates and reports fourth quarter and full year 2022 financial results.
MDGL Ratings Summary
MDGL Quant Ranking